Compass Pathways has appointed Kelley Boucher as Chief People Officer, effective immediately, as it scales development of COMP360 psilocybin for psychiatry.

Kelley Boucher joins Compass Pathways as Chief People Officer to support scaling towards bringing COMP360, its proprietary synthetic psilocybin, into psychiatry. The compound is being developed for treatment-resistant depression and PTSD, with FDA Breakthrough Therapy and UK ILAP designations; potential FDA review or approval is targeted for the first half of 2027, subject to regulatory progress and funding.